You are here

Survey: Induction of Remission Influences Prescribing Decisions in RA

Improved remission remains key unmet need (June 19)

Decision Resources, a research and advisory firm based in Burlington, Mass., finds that, for the treatment of rheumatoid arthritis (RA), the majority of surveyed U.S. and European rheumatologists cite a therapy’s induction of remission as one of the attributes that most influences their prescribing decisions.

More than 60% and 70% of U.S. and European rheumatologists, respectively, rank the percentage of patients achieving remission at 6 months as one of the top three most persuasive endpoints when prescribing a new drug for RA.

In the survey, rheumatologists also indicated that there is a moderate unmet need for therapies with a greater ability to induce remission. Therapies with a greater ability to induce remission at 6 months have an opportunity for product differentiation.

The report also finds that, according to interviewed thought leaders and clinical data, tocilizumab (Actemra, Roche) has a minor advantage over adalimumab (Humira, AbbVie/Eisai) because of its ability to effect remission at 6 months, whereas tofacitinib (Xeljanz, Pfizer/Takeda) is at a disadvantage to adalimumab on this endpoint.

“However, in spite of thought-leader opinion and clinical trial-data support for IV tocilizumab’s excellent efficacy, the drug is predominantly used as a later-line biologic because of payer restrictions, concerns about monitoring and managing its side effects, its more-limited postmarketing experience, and its need for IV infusion,” said analyst Madhuri Borde, PhD.

Source: Decision Resources; June 19, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs